Validation of analytical methods in GMP: The disposable Fast Read 102® device, an alternative practical approach for cell counting

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Gunetti, Monica ^a   Castiglia, Sara ^a   Rustichelli, Deborah ^a   Mareschi, Katia ^a,b   Sanavio, Fiorella ^a   Muraro, Michela ^a   Signorino, Elena ^a   Castello, Laura ^a   Ferrero, Ivana ^a,b   Fagioli, Franca ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cell count; Cell factory; Cell therapy; GMP; Validation methods

Indexed keywords

REAGENT; TRYPAN BLUE; TUERK SOLUTION; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; BURKER CHAMBER; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DATA ANALYSIS; DILUTION; DISPOSABLE EQUIPMENT; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; QUALITY CONTROL; REPRODUCIBILITY; VALIDATION PROCESS; WASTE DISPOSAL;

HUMANS; LABORATORIES; QUALITY CONTROL; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 84861638403     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-112     Document Type: Article

References (25)

1. Committee for Human Medicinal Products (CHMP) Guidelines on Human Cell-Based Medicinal Products European Medicines Agency, Doc. Ref. EMEA/CHMP/410869/2006, Committee for Human Medicinal Products (CHMP).
2. European Parliament and Council Directive 2001/83/EC of 2001/83/EC of 6th November 2001 on the community code relating to medicinal products for human use,
3. European Parliament and Council Directive 2004/23/EC of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells,
4. Italian Parliament Legislative decree N. 191/2007 of the to adopt EC Directive 2004/23/EC,
5. European Parliament and of the Council Regulation (EC) N. 1394/2007 of 13 November 2007 on advanced therapy medicinal products,
6. European Commission The Rules Governing Medical Products in European Union. Good manufacturing practices. 1997, 4. European Commission.
7. Points to Consider on the Manufacture and Quality Control of Human Somatic Cell Therapy Medicinal Products (EMEA CPMP/BWP/41450/98), 1998,
8. European Parliament and Council Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001,
9. International conference on the harmonization of technical requirements for the registration of pharmaceuticals for human use. ICH harmonized tripartite guideline validation of analytical procedures: text and methodology Q2 (R1), 2005, Current Step 4 version, Parent Guideline dated 27 October 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005).
10. European Pharmacopoeia 2011, European Directorate for the Quality of Medicines & HealthCare (EDQM), 7.
11. FDA Title 21 CFR Part 11. Electronic Records; Electronic Signatures; Final Rule,
12. FDA Guidance for Industry Part 11, Electronic Records. Electronic Signatures - Scope and Application, 2003,
13. Guidance for Industry Computerized Systems Used in Clinical Investigations, 2007,
14. EudraLex. The Rules Governing Medicinal Products in the European Union. Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, Annex 11: Computerised Systems, 2011, Volume 4.
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Horwitz E, Prockop D. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317. 10.1080/14653240600855905, 16923606.
16. Mareschi K, Rustichelli D, Calabrese R, Gunetti M, Sanavio F, Castiglia S, Risso A, Ferrero I, Fagioli F. Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use. Stem Cell International in press.
17. Bieback K, Schallmoser K, Klüter H, Strunk D. Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother. 2008, 35:286-294. 3076361, 21512644.
18. Bieback K, Kinzebach S, Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2011, 20. 2010:193519.
19. Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy. World J Stem Cells 2010, 2:81-92. 3097927, 21607124.
20. Soncin S, Lo Cicero V, Astori G, Soldati G, Gola M, Sürder D, Moccetti T. A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice. J Transl Med 2009, 7:78. 10.1186/1479-5876-7-78, 2753319, 19737416.
21. European Parliament and Council Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use,
22. Legislative decree N. 211/2003. Adoption of EC Directive 2001/20/EC related to the application of the good clinical practice in the execution of the clinical experimentations of medicines for clinical use,
23. European Parliament and Council Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products,
24. Legislative Decree N. 200/2007, Application of European Commission Directive 2005/28/EC of 8 April 2005 laying down the principles and detailed guidelines for good clinical practice concerning investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products.
25. Italian Minister of Health Decree dated 21st December 2007 on the procedure to follow for the authorization to the competent authority, for the communication of substantial amendments and the declaration of conclusion of the clinical trial and for the application to seem to the ethical committee,